Cargando…

(18)F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study

Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) frequently induces tumor response in metastatic melanoma patients. However, tumor response often takes months and may be heterogeneous. Consequently, additional local treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nienhuis, Pieter H., Antunes, Inês F., Glaudemans, Andor W.J.M., Jalving, Mathilde, Leung, David, Noordzij, Walter, Slart, Riemer H.J.A., de Vries, Erik F.J., Hospers, Geke A.P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society of Nuclear Medicine 2022
Materias:	Clinical (Oncology: Melanoma/Skin)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157735/ https://www.ncbi.nlm.nih.gov/pubmed/34503964 http://dx.doi.org/10.2967/jnumed.121.262368

Ejemplares similares

Image Quality and Interpretation of [(18)F]-FES-PET: Is There any Effect of Food Intake?
por: Boers, Jorianne, et al.
Publicado: (2020)

Use of S-100B to Evaluate Therapy Effects during Bevacizumab Induction Treatment in AJCC Stage III Melanoma
por: Kruijff, S., et al.
Publicado: (2011)

Quality of Life After Axillary or Groin Sentinel Lymph Node Biopsy, With or Without Completion Lymph Node Dissection, in Patients With Cutaneous Melanoma
por: de Vries, Mattijs, et al.
Publicado: (2009)

Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy
por: Bloemendal, Martine, et al.
Publicado: (2019)

Detection of Melanoma Nodal Metastases; Differences in Detection Between Elderly and Younger Patients Do Not Affect Survival
por: Kruijff, S., et al.
Publicado: (2010)

Nodular Histologic Subtype and Ulceration are Tumor Factors Associated with High Risk of Recurrence in Sentinel Node-Negative Melanoma Patients
por: Faut, Marloes, et al.
Publicado: (2016)

S-100B Concentrations Predict Disease-Free Survival in Stage III Melanoma Patients
por: Kruijff, S., et al.
Publicado: (2009)

Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites?
por: Wevers, K. P., et al.
Publicado: (2012)

Risk Factors for Positive Deep Pelvic Nodal Involvement in Patients with Palpable Groin Melanoma Metastases: Can the Extent of Surgery be Safely Minimized?: A Retrospective, Multicenter Cohort Study
por: Oude Ophuis, C. M. C., et al.
Publicado: (2015)

Lymphatic Drainage Patterns from Melanomas on the Shoulder or Upper Trunk to Cervical Lymph Nodes and Implications for the Extent of Neck Dissection
por: Veenstra, Hidde J., et al.
Publicado: (2012)

Isolated Tumor Cells and Long-Term Prognosis of Patients with Melanoma
por: van Akkooi, A. C. J., et al.
Publicado: (2008)

Cutaneous Melanoma and Sentinel Lymph Node Biopsy
por: van Akkooi, A. C. J., et al.
Publicado: (2008)

COVID-19 is Affecting the Presentation and Treatment of Melanoma Patients in the Northeastern United States
por: Davis, Catherine H., et al.
Publicado: (2021)

A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis
por: Vreeland, Timothy J., et al.
Publicado: (2021)

The MelFo Study UK: Effects of a Reduced-Frequency, Stage-Adjusted Follow-Up Schedule for Cutaneous Melanoma 1B to 2C Patients After 3-Years
por: Moncrieff, Marc D., et al.
Publicado: (2020)

Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
por: Thompson, John F., et al.
Publicado: (2014)

Therapeutic Surgical Management of Palpable Melanoma Groin Metastases: Superficial or Combined Superficial and Deep Groin Lymph Node Dissection
por: van der Ploeg, A. P. T., et al.
Publicado: (2011)

The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma
por: Dieng, Mbathio, et al.
Publicado: (2022)

The MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients—Results after 1 Year
por: Damude, Samantha, et al.
Publicado: (2016)

Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure?
por: Jonker, Daphne L., et al.
Publicado: (2018)

In Sentinel Node-Positive Melanoma Patients, Does Omission of Completion Lymph Node Dissection Make More Intensive Follow-Up Necessary, and Does Adjuvant Systemic Therapy Permit Less Intensive Follow-Up?
por: Thompson, John F.
Publicado: (2021)

The MELFO Study: A Multicenter, Prospective, Randomized Clinical Trial on the Effects of a Reduced Stage-Adjusted Follow-Up Schedule on Cutaneous Melanoma IB–IIC Patients—Results After 3 Years
por: Deckers, Eric A., et al.
Publicado: (2019)

Focused Ultrasound Surveillance of Lymph Nodes Following Lymphoscintigraphy Without Sentinel Node Biopsy: A Useful and Safe Strategy in Elderly or Frail Melanoma Patients
por: Ipenburg, Norbertus A., et al.
Publicado: (2019)

Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study
por: Moncrieff, Marc D., et al.
Publicado: (2022)

Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases
por: Lawless, Anna K., et al.
Publicado: (2022)

Outcome After Therapeutic Lymph Node Dissection in Patients with Unknown Primary Melanoma Site
por: Prens, Sebastiaan P., et al.
Publicado: (2011)

Trends in Sentinel Lymph Node Biopsy Enactment for Cutaneous Melanoma
por: El Sharouni, Mary-Ann, et al.
Publicado: (2019)

Oncological Outcome After Lymph Node Dissection for Cutaneous Squamous Cell Carcinoma
por: Huis in ’t Veld, Eva A., et al.
Publicado: (2023)

Risk Stratification of Sentinel Node Metastasis Disease Burden and Phenotype in Stage III Melanoma Patients
por: Hussain, Zahra, et al.
Publicado: (2022)

Morbidity After Inguinal Lymph Node Dissections: It Is Time for a Change
por: Faut, Marloes, et al.
Publicado: (2016)

Improved Perioperative Seroma and Complication Rates Following the Application of a 2-Layer Negative Pressure Wound Therapy System After Inguinal Lymphadenectomy for Metastatic Cutaneous Melanoma
por: Moncrieff, Marc D., et al.
Publicado: (2020)

Potential Cost-Effectiveness of US-Guided FNAC in Melanoma Patients as a Primary Procedure and in Follow-Up
por: van Akkooi, Alexander C. J., et al.
Publicado: (2009)

20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters
por: Deroose, Jan P., et al.
Publicado: (2011)

PET imaging of an optimized anti-PD-L1 probe (68)Ga-NODAGA-BMS986192 in immunocompetent mice and non-human primates
por: Zhou, Huimin, et al.
Publicado: (2022)

Baseline Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study
por: Wade, Ryckie G., et al.
Publicado: (2018)

Multimarker Reverse Transcriptase-Polymerase Chain Reaction Assay in Lymphatic Drainage and Sentinel Node Tumor Burden
por: Rutkowski, Piotr, et al.
Publicado: (2010)

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
por: Andtbacka, Robert H. I., et al.
Publicado: (2016)

Combined Analysis of Phase III Trials Evaluating [(99m)Tc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma
por: Sondak, Vernon K., et al.
Publicado: (2012)

1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study
por: Moncrieff, Marc D., et al.
Publicado: (2018)

Different Scoring Methods of FDG PET/CT in Giant Cell Arteritis: Need for Standardization
por: Stellingwerff, Menno D., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_uhdu7qdspcs9gtn95fif471128